

NEWS RELEASE

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR IN ANY OTHER JURISDICTION OUTSIDE SINGAPORE

NANOFILM TECHNOLOGIES INTERNATIONAL LIMITED RECEIVES STRONG DEMAND FOR IPO

- ***Public Offer Shares 30.6 times subscribed¹***
- ***At the same time as, but separate from, the Offering, 13 cornerstone investors including Venezia Investments Pte. Ltd., an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited, certain funds advised by Capital Research and Management Company, Employees Provident Fund Board, Aberdeen Standard Investments (Asia) Limited, AIA Investment Management Private Limited and Lion Global Investors Limited, have subscribed for an aggregate of 104,256,100 Cornerstone Shares***
- ***The Offering and the issuance and sale of the Cornerstone Shares will raise gross proceeds of approximately S\$470.1 million (assuming that the Over-allotment Option is not exercised)***
- ***Nanofilm will be the first nanotechnology solutions provider to list on SGX-ST***
- ***Commencement of trading of Shares is expected to be at 9.00 a.m. on 30 October 2020***

SINGAPORE, 29 October 2020 – Nanofilm Technologies International Limited (the “**Company**”, and together with its subsidiaries, “**Nanofilm**” or the “**Group**”), a leading provider of nanotechnology solutions in Asia, received strong support from institutional, high net worth and retail investors for its initial public offering (the “**Offering**”), in conjunction with the Company’s proposed listing on the Mainboard of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”).

¹ Excluding applications by connected persons and persons mentioned in Rule 240 of the SGX-ST Listing Manual.

Dr Shi Xu (史旭), Executive Chairman of the Company, said, “As the first nanotechnology solutions provider to list in Singapore, this is a strong vote of confidence for our Group and a recognition of our established track record and growth plans. We would like to take this opportunity to thank our investors for their support, as we strive to bring the business to new heights and continue to redraw the boundaries of material science.”

The Offering, which is subject to an Over-allotment Option, comprised 77,236,200 Offering Shares offered by existing shareholders of the Company, Dr Shi Xu, Mr Lee Liang Huang and Dr Wei Hao (together, the “**Vendors**”), at the Offering Price of S\$2.59 each, as follows: (i) an international placement of 73,374,300 Offering Shares to investors (the “**Placement Shares**”), including institutional and other investors in Singapore, outside the United States of America (the “**U.S.**”) in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the “**International Offering**”), and (ii) an offering of 3,861,900 Offering Shares (the “**Public Offer Shares**”, and together with the Placement Shares, the “**Offering Shares**”) by way of a public offer in Singapore (the “**Singapore Public Offer**”).

At the close of the Singapore Public Offer at 12.00 noon on 28 October 2020, there were 8,678¹ valid applications for the 3,861,900 Public Offer Shares. These applicants applied for an aggregate of 118,028,400¹ Public Offer Shares, with application monies received amounting to approximately S\$305.7 million, which translates to the Singapore Public Offer being approximately 30.6 times subscribed.

Strong indications of interests were also received for the Placement Shares. Of the 73,374,300 Placement Shares available under the International Offering, indications of interest were received for 1,683,379,067¹ Placement Shares, resulting in the International Offering being approximately 22.9 times subscribed. Based on the 77,236,200 Offering Shares available for subscription under the Offering (assuming that the Over-allotment Option is not exercised), the Offering was overall 23.3 times subscribed¹.

Mr Lee Liang Huang (李良煌), Chief Executive Officer of the Company, said, “As we embark on our next growth phase, our listing will provide us with a new launch pad, capital and a platform to attract talents across multiple industry segments. Simultaneously, we hope that our advanced materials and nanotechnology business units will play an enabling and catalytic role, allowing us to commercialise our technology across a wider range of applications and industries.”

Concurrently with, but separate from, the Offering, each of Aberdeen Standard Investments (Asia) Limited, AIA Investment Management Private Limited, Avanda Investment Management Pte Ltd, Credit Suisse AG, Singapore Branch and Credit Suisse AG, Hong Kong Branch (on behalf of certain of their private banking clients), Eastspring Investments (Singapore) Limited, Employees Provident Fund Board, Fullerton Fund Management Company Ltd., JPMorgan Asset Management (Singapore) Limited, Lion Global Investors Limited, Nikko Asset Management Asia Limited, Principal Asset Management (S) Pte Ltd, SMALLCAP World Fund, Inc. and American Funds Insurance Series—Global Small Capitalization Fund (which are funds advised by Capital Research and Management Company) and Venezia Investments Pte. Ltd. (an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited) (collectively, the “**Cornerstone Investors**”) has entered into separate cornerstone agreements with the Company and/or Dr Shi Xu to subscribe for or purchase an aggregate of 104,256,100 Shares at the Offering Price (the “**Cornerstone Shares**”), representing a 15.8% stake in the Company immediately after completion of the Offering and the issuance and sale of the Cornerstone Shares.

Immediately upon completion of the Offering and the issuance and sale of the Cornerstone Shares, Nanofilm's total number of issued and outstanding shares will be 658,351,110 Shares and its market capitalisation is expected to be approximately S\$1,705 million, based on the Offering Price of S\$2.59. The estimated net proceeds from the Offering and issuance and sale of the Cornerstone Shares, after deducting underwriting commissions and estimated expenses in relation to the Offering payable by the Company and the Vendors but excluding any discretionary incentive fees, will be approximately S\$452.5 million (assuming that the Over-allotment Option is not exercised), of which approximately S\$190.9 million will be due to the Company.

The listing and trading of the Company's shares is expected to commence on a “Ready” basis at 9.00 a.m. on Friday, 30 October 2020, under the stock code “MZH”.

Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited are the joint issue managers for the Offering. Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited are the joint global coordinators for the Offering. Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Singapore) Limited, CLSA Singapore Pte Ltd and Oversea-Chinese Banking Corporation Limited are the joint bookrunners and underwriters for the Offering. Evercore Asia (Singapore) Pte. Ltd. is the financial adviser for the Offering.

- ENDS -

ABOUT NANOFILM TECHNOLOGIES INTERNATIONAL LIMITED

Nanofilm Technologies International Limited (“**Nanofilm**”) is a leading provider of nanotechnology solutions in Asia, leveraging its proprietary technologies, core competencies in R&D, engineering and production, to provide technology-based solutions across a wide range of industries. Nanofilm’s solutions serve as key catalysts enabling its customers to achieve high value-add advancements in their end-products in an environmentally sustainable manner.

Nanofilm offers surface solutions based on vacuum deposition, including using its patented Filtered Cathodic Vacuum Arc (“**FCVA**”) technology. Nanofilm’s nanotechnology-based solutions are utilised in a wide range of industries such as computer, communications and consumer electronics (“**3C**”), automotive, precision engineering, and printing and imaging.

This media release is issued on behalf of Nanofilm Technologies International Limited by Citigate Dewe Rogerson. For media queries, please contact:

Citigate Dewe Rogerson Singapore Pte Ltd

Chia Hui Kheng / Dolores Phua / Joey Ho

T +65 6589 2361 / 6589 2383 / 6589 2376 (Office Hours)

E huikheng.chia@citigatedewerogerson.com / dolores.phua@citigatedewerogerson.com / joey.ho@citigatedewerogerson.com

Important Notice:

Capitalised words and expressions used in this media release and not otherwise defined shall have the meanings given to them in the Prospectus of Nanofilm dated 23 October 2020.

The information and views expressed in this news release are based on, and qualified in their entirety by information found in the Prospectus issued by Nanofilm Technologies International Limited. Certain information in the Prospectus was provided by Frost & Sullivan Pte Ltd (“Frost & Sullivan”), an independent industry consultant who was commissioned to prepare a report on the global advanced materials industry for the purpose of inclusion in the Prospectus, including data (actual, estimated and forecast) relating to, among other things, demand and market share information. Certain of the information in this news release is historical information. The past performance of Nanofilm is not indicative of its future performance.

This news release includes forward-looking statements provided with respect to the anticipated financial position, business strategies, future plans and prospects of Nanofilm and its subsidiaries. These forward-looking statements are only predictions, and there can be no assurance that such forward-looking statements will be realised. Nanofilm’s actual results may vary from the anticipated results and such variation may be material. No representations or warranties are made as to the accuracy or reasonableness of these forward-looking statements.

This news release is for information purposes only and does not constitute or form part of any offer for sale or subscription or invitation or solicitation of any offer to buy or subscribe for any securities in any jurisdiction nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment or any investment decision whatsoever.

Neither this news release nor any copy or portion of it may be sent or taken, transmitted or distributed, directly or indirectly, into the United States (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been, and will not be, registered under the Securities Act, or the securities laws of any state of the U.S. and the Shares may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws. This new release is not an offer for sale of securities in the United States. There will be no public offering of Shares in the United States.

This news release may be restricted by law in certain jurisdictions. Persons who may come into possession of this news release are advised to consult with their own legal advisers as to what restrictions may be applicable to them and to observe such restrictions. This news release may not be used for the purpose of an offer or invitation in any circumstances. Neither this news release nor any of its content may be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Information contained in this news release does not constitute a part of the preliminary prospectus or Prospectus. Failure to comply with these restrictions may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited, as the joint issue managers for the Offering, Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited, as the joint global coordinators for the Offering, Citigroup Global Markets Singapore Pte. Ltd., CLSA Singapore Pte Ltd, Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited, as the joint bookrunners and underwriters for the Offering, and Evercore Asia (Singapore) Pte. Ltd. as the financial adviser for the Offering, assume no responsibility for the contents of this news release.

This news release has not been reviewed by the Monetary Authority of Singapore.